EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention

Jannifer Jasmin Thavarajah, Bo Langhoff Hønge, Christian Morberg Wejse iD

Viruses · 2024

DOI: 10.3390/v16060911 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, 2024. Verfasst von Jannifer Jasmin Thavarajah und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health, Aarhus University, 8000 Aarhus C, Denmark. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, HIV Antibodies, Antibodies, Neutralizing. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Danmarks Frie Forskningsfond, Independent Research Fund Denmark.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although antiretroviral therapy (ART) effectively halts disease progression in HIV infection, the complete eradication of the virus remains elusive. Additionally, challenges such as long-term ART toxicity, drug resistance, and the demanding regimen of daily and lifelong adherence required by ART highlight the imperative need for alternative therapeutic and preventative approaches. In recent years, broadly neutralizing antibodies (bNAbs) have emerged as promising candidates, offering potential for therapeutic, preventative, and possibly curative interventions against HIV infection.

Objective

This review aims to provide a comprehensive overview of the current state of knowledge regarding the passive immunization of bNAbs in HIV-1-infected individuals. Main findings: Recent findings from clinical trials have highlighted the potential of bNAbs in the treatment, prevention, and quest for an HIV-1 cure. While monotherapy with a single bNAb is insufficient in maintaining viral suppression and preventing viral escape, ultimately leading to viral rebound, combination therapy with potent, non-overlapping epitope-targeting bNAbs have demonstrated prolonged viral suppression and delayed time to rebound by effectively restricting the emergence of escape mutations, albeit largely in individuals with bNAb-sensitive strains. Additionally, passive immunization with bNAb has provided a “proof of concept” for antibody-mediated prevention against HIV-1 acquisition, although complete prevention has not been obtained. Therefore, further research on the use of bNAbs in HIV-1 treatment and prevention remains imperative.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV-1HIV AntibodiesAntibodies, NeutralizingHumansImmunization, PassiveBroadly Neutralizing AntibodiesAnti-HIV AgentsAnimals

Stichwörter der Autor:innen

HIV-1broadly neutralizing antibodiesclinical trialcure strategypreventionremissiontreatment

Substanzen

HIV AntibodiesAntibodies, NeutralizingBroadly Neutralizing AntibodiesAnti-HIV Agents

Autor:innen und Institutionen

  • Faculty of Health, Aarhus University, 8000 Aarhus C, Denmark.
  • Clinical Medicine, Department of Infectious Diseases, Aarhus University Hospital, 8200 Aarhus N, Denmark.
  • GloHAU, Center of Global Health, Department of Public Health, Aarhus University, 8000 Aarhus C, Denmark.

ORCID-Profile: Christian Morberg Wejse

Förderung

  • Danmarks Frie Forskningsfond
  • Independent Research Fund Denmark

Zitieren

APA

Thavarajah, J. J., Hønge, B. L., & Wejse, C. M. (2024). The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention. Viruses. https://doi.org/10.3390/v16060911

Vancouver

Thavarajah JJ, Hønge BL, Wejse CM. The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention. Viruses. 2024. doi:10.3390/v16060911

BibTeX
@article{Thavarajah2024,
  author = {Thavarajah, Jannifer Jasmin and Hønge, Bo Langhoff and Wejse, Christian Morberg},
  title = {The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16060911}
}
Kostenlos starten →